Minurin Flas (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidneys, which promotes water reabsorption through aquaporin‑2 channels. The same receptor activation in endothelial cells triggers release of von Willebrand factor and factor VIII, supporting normal blood clotting.

The dosage of Minurin Flas is individualized by the prescribing clinician based on the specific indication, patient age, weight, and renal function. Only a qualified healthcare professional should determine the appropriate dose and administration schedule.

Safety data for desmopressin acetate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Minurin Flas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with traditional vasopressin preparations, desmopressin acetate has a longer half‑life, greater selectivity for V2 receptors, and a reduced risk of vasoconstrictive side effects. This makes it preferable for chronic management of diabetes insipidus and for haemostatic use, while still requiring careful monitoring of fluid balance.

Minurin Flas should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the stability and potency of the sublingual formulation throughout its shelf life.

The product is supplied as a sublingual formulation. Patients place the dose under the tongue and allow it to dissolve completely without swallowing immediately, ensuring optimal absorption through the oral mucosa.

The most critical safety concerns are severe hyponatraemia leading to seizures, pulmonary oedema from fluid overload, and rare thrombotic events. Prompt recognition of symptoms such as confusion, headache, or sudden weight gain is essential, and patients should be monitored closely.

Minurin Flas is contraindicated in patients with known hypersensitivity to desmopressin acetate, uncontrolled hypertension, or those who cannot adhere to fluid‑restriction guidelines. Caution is also advised for individuals with severe renal impairment or a history of hyponatraemia.